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Gene expression studies on breast cancer have generally been performed on tissue obtained at the time of surgery. In this study,
we have compared the gene expression profiles in preoperative tissue (core needle biopsies) while tumor is still in its normal
milieu to postoperative tissue from the same tumor obtained during surgery. Thirteen patients were included of which eleven
had undergone sentinel node diagnosis procedure before operation. Microarray gene expression analysis was performed using
total RNA from all the samples. Paired significance analysis of microarrays revealed 228 diﬀerently expressed genes, including
several early response stress-related genes such as members of the fos and jun families as well as genes of which the expression has
previously been associated with cancer. The expression profiles found in the analyses of breast cancer tissue must be evaluated with
caution. Diﬀerent profiles may simply be the result of diﬀerences in the surgical trauma and timing of when samples are taken and
not necessarily associated with tumor biology.
1. Introduction
Breast cancer is detected either by clinical signs such as
palpable tumour or in mammographic screening. In both
cases biopsies are taken from the tumour to determine
whether the tumour is benign or malign. If malignancy is
detected, the patient will be scheduled for surgery within a
few weeks. Before the surgery, sentinel node (SN) diagnostics
is generally performed to examine the spread of cancer cells
to axillary lymph nodes. The SN can be identified using a
blue dye, a radioactive colloid, or a combination of the two
[1, 2].
Microarray technology enables scientists to study thou-
sands of genes simultaneously. The resulting molecular
profile can be used to study complex multifactorial diseases
such as breast cancer [3, 4]. Gene signatures have been
shown to correlate with clinically relevant clinicopatho-
logical parameters and prognosis [5–7]. These molecular
signatures may be used to predict the individuals for whom
therapy is beneficial and spare unnecessary treatment for
over 80% of the others [6, 8–10].
The time of procurement, which refers to the point of
when the biopsies are taken [11] as well as the postoperative
handling [12], has been found to be a confounding factors
in microarray data analysis in breast cancer. Most of the pre-
viously published studies consist of tumour tissue taken in
connection to surgery. Biopsies taken from the tumour, while
the tumour is within the breast prior to any manipulation,
must be as near to the true expression state as possible. In
this study, we analyzed whether there are diﬀerences in genes
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expressed in preoperative biopsies obtained in connection
with mammography and postoperative biopsies taken from
the tumour immediately after its removal from the patient.
2. Materials and Methods
2.1. Patients. This study includes 13 patients from which
both a pre- and postoperative samples were available.
Histopathological characteristics are listed in Table 1. All
of the patients had been operated with ablatio mammae
(surgical removal of the entire breast). Sentinel node diag-
nostics using 99m Tc-labelled colloids were performed in
eleven patients as a part of the surgical procedure [13],
while the remaining two underwent direct complete axillary
dissection. No recurrence of disease has been observed so far
for these patients, but the follow-up time is short. All women
participating in this study have signed an informed consent
and the study design is approved by the Regional Committee
for Medical and Health Research Ethics (REK).
2.2. Tissue Collection. Preoperative needle biopsies were
obtained by an experienced radiologist using a 16 Gauge
core needle device through a small skin incision in a sterile
field. Three samples were processed for routine histological
diagnosis while one sample for molecular analysis was put
directly into RNAlater (Sigma Aldrich, St Louis, MO, USA).
The postoperative samples were taken by the breast cancer
surgeon upon removal of the breast and were preserved in
RNAlater. The RNAlater-stabilised tissue samples were stored
at −80◦C. The time delay between the sampling of the pre-
and postoperative specimens were 2–8 weeks.
2.3. RNA Isolation. RNA was prepared using the method
of Wei and Khan [14] but modified to also include
miRNA. Briefly, frozen tissue samples were homogenized in
TriReagent (Ambion, Austin, TX, USA) using a 5mm steal
bead in a Mixer Mill MM301 (Retsch, Haan, Germany) at 30
Hz for 2min. After phase separation with 0.2 vol chloroform,
the aqueous phase (containing RNA) was mixed with 1.5 vol
100% ethanol and transferred to RNeasy Mini columns
(Qiagen, Hilden, Germany). Further processing (including
on-column DNase digestion) was per the manufacturer’s
protocol and the purified RNA was eluted with RNase-free
water. RNA concentration was measured using NanoDrop
ND-1000 UV-VIS Spectrophotometer (Thermo Fisher Sci-
entific, Waltham, MA, USA) and the RNA quality analyzed
on a 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). The
purified RNA was stored at −80◦C.
2.4. Microarray Analysis. mRNA amplification, labelling,
and hybridization were done following the manufacturer’s
instructions (Agilent One-Color Microarray-Based Gene
Expression Analysis; Version 5.7). Briefly, 500 ng RNA was
amplified and labelled with Cy3 using the Quick Amp
labelling kit and the labelled cRNA purified using the Qiagen
RNeasy Mini Kit. Amplification and labelling eﬃciency
were controlled on the NanoDrop before 1.65 μg cRNA was
fragmented and applied to Agilent Whole Human Genome
4 × 44 k microarrays (G4112F). After hybridisation for 17 h
at 65◦C the microarray slides were washed and scanned
with the Agilent Microarray Scanner. Microarray data were
extracted using Agilent Feature Extraction (v. 10.7.1.1) and
further quantile normalized and analyzed using J-Express
2009 [15]. For expression values the gProcessedSignal from
Feature Extraction were used and controls and bad spots
were filtered with maximum 20% allowed missing values.
The expression values were log2-transformed and missing
values imputed using the LSImpute Adaptivemethod. Diﬀer-
ential expression was analyzed using SAM as implemented in
J-Express with 1000 permutations and only genes with false
discovery rate (FDR)< 2.5%were considered significant. The
microarray data are available at the ArrayExpress Archive
(http://www.ebi.ac.uk/microarray-as/ae/) accession number
E-MTAB-470.
Gene functional classification of the significant genes was
performed using DAVID [16, 17] and pathway analysis was
done through the use of Ingenuity Pathways Analysis (IPA;
Ingenuity Systems, Redwood City, CA, USA).
2.5. Quantitative RT-PCR. To confirm the results of the
microarray experiment, qRT-PCR using TaqMan low density
arrays (Applied Biosystems, Carlsbad, CA, USA) were per-
formed using primer-probe pairs for 13 of the significant
genes (Table 2). The genes were selected to contain both
up- and downregulated genes. 500 ng RNA was reverse
transcribed using the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems) per the manufacturer’s
instructions. Due to lack of material, qRT-PCR was only
performed for ten of the sample pairs. The samples were
further processed using TaqMan Gene Expression Master
Mix (Applied Biosystems) and run on the 7900HT Real-
Time PCR System (Applied Biosystems) as per the manufac-
turer’s instructions. Relative changes in gene expression were
analyzed using the ΔΔCt-method [18] with the preoperative
sample as control sample for each pair. As endogenous
controls the average of GAPDH, 18S, and ACTB were
used.
3. Results
3.1. mRNA Expression. RNA was isolated from match-
ing samples taken both before and after breast cancer
surgery of 13 patients. After filtering, expression data were
available from 24,105 diﬀerent probes representing 18,189
diﬀerent genes. Comparing the gene expressions of the
13 pairs showed that there was relatively little diﬀerence
between the pre- and postoperative samples (Figures 1(a)
and 1(b) and Supplementary Figure 1 available online
at doi:10.5402/2012/450267). Paired significance analysis
of microarrays (SAM) [19], however, showed diﬀerently
expression for 235 probes with false discovery rate (FDR)
<2.5%, corresponding to 228 diﬀerent genes (Supplementary
Table 1) that separates the pre- and postoperative samples
(Figures 1(c) and 1(d) and Supplementary Figure 2). The
majority (201) of these genes were upregulated and only
27 were downregulated in the postoperative samples. The
diﬀerentially expressed genes contained genes involved in
early response such as FOSB, response to oxidative stress such
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Table 1: Histopathological characteristics of the patients included in the study.
Case Age Tumour
type∗
TNM Tumour
size (cm)
Preoperative Postoperative
Tumor content
(%)
ER† (%) PGR† HER2† Tumor content
(%)
ER† (%) PGR†
2 54 IDC T2gr3N2M0 4.3 30 + (>50) − + 30 − −
3 42 IDC T2gr3N0M0 4.8 40 − − − 60 − −
4 67 IDC T2gr2N1M0 3.5 50 + (>50) + − 55 + (>50) +
5 82 IDC T1cgr3N0M0 1.8 30 + (>50) + − 40 + (>50) +
6 52 IDC T2gr3N3M0 2.0 5 − − + 5 − −
7 68 IDC T1cgr3N1M0 1.3 35 + (>50) − + 40 + (>50) +
8 76 IDC T1cgr2N0M0 1.4 40 − − − 35 − −
9 70 IDC T1bgr1N0M0 0.9 25 + (>50) + − 25 + (>50) +
10 77 IDC T2gr3N1M0 2.6 50 + (>50) − − 15 + (>50) −
11 61 IDC T2gr3N1M0 2.5 50 − − + 40 − −
13 79 IDC T2gr3N0M0 2.3 45 + (>10) − + 55 + (>1) −
14 70 IDC T2gr2N0M0 2.3 35 + (>50) + − 35 + (>50) +
15 68 ILC T2gr2N0M0 2.5 50 + (>50) − 30 + (>50) +
∗
IDC: infiltrating ductal carcinoma; ILC: infiltrating lobular carcinoma.
†ER: oestrogen receptor status; PR: progesterone receptor status; HER2: HER2 receptor status.
Table 2: TaqMan assays used for validation qRT-PCR and correlation between the microarray and the qRT-PCR results. The P values given
are for positive correlation. r: Pearson’s product-moment correlation.
Gene Array probe ID TaqMan assay ID Task r P
18S NA Hs99999901 s1 Endogenous control NA NA
ACTB
A 23 P31323
A 24 P226554
A 24 P226554
A 32 P137939
Hs99999903 m1 Endogenous control 0.904 1.7E − 4
ANGEL2 A 24 P28622 Hs00404357 m1 Target 0.238 0.254
CYP2D6
A 23 P143734
A 23 P155123 Hs02576167 m1 Target 0.262 0.232
CYR61
A 23 P46426
A 24 P370946 Hs00155479 m1 Target 0.894 2.4E − 4
DUSP1 A 23 P110712 Hs00610256 g1 Target 0.983 1.7E − 7
DUSP9 A 24 P417189 Hs00154830 m1 Target −0.630 0.965
EVI2B A 23 P66694 Hs00272421 s1 Target 0.945 1.8E − 5
FOSB A 23 P429998 Hs00171851 m1 Target 0.749 0.006
GAPDH A 23 P13899 Hs99999905 m1 Endogenous control 0.632 0.025
MALAT1 A 24 P497244 Hs00273907 s1 Target 0.332 0.174
MAPK3 A 23 P37910 Hs00385075 m1 Target −0.018 0.520
NFRκB A 23 P24485 Hs00196269 m1 Target −0.169 0.680
PTPRE
A 24 P213494
A 24 P213503 Hs00369944 m1 Target 0.413 0.118
RASD1
A 24 P348006
A 23 P118392 Hs02568415 s1 Target 0.797 0.003
TMEM19 A 24 P358976 Hs00217586 m1 Target 0.248 0.245
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Table 3: Selected genes that are diﬀerently expressed between pre- and postoperative samples.
Gene name Agilent ID Description
SAM Fold Change
Called FDR q-val Mean Range
CX3CL1 A 24 P390495
Chemokine (C-X3-C motif) ligand 1
(CX3CL1), mRNA (NM 002996) 21 0 0 2.99 0.90–4.09
CYP2D6
A 23 P143734 Cytochrome P450, family 2, subfamily D,
polypeptide 6 (CYP2D6), transcript
variant 1, mRNA (NM 000106)
18 0 0 1.65 0.58–3.55
A 23 P155123 103 2.08 1.55 1.51 0.46–3.38
CYR61
A 23 P46426 Cysteine-rich, angiogenic inducer, 61
(CYR61), mRNA (NM 001554)
163 1.75 1.65 4.07 0.61–12.88
A 24 P370946 196 1.82 1.79 5.51 0.36–22.80
DUSP1 A 23 P110712
Dual specificity phosphatase 1 (DUSP1),
mRNA (NM 004417) 217 2.3 2.20 3.18 0.49–12.69
DUSP9 A 24 P417189
Dual specificity phosphatase 9 (DUSP9),
mRNA (NM 001395) 7 0 0 2.12 1.15–2.88
FOSB A 23 P429998
FBJ murine osteosarcoma viral oncogene
homolog B (FOSB), transcript variant 1,
mRNA (NM 006732)
203 2.11 2.01 2.79 0.96–24.26
MALAT1 A 24 P497244
Metastasis associated lung
adenocarcinoma transcript 1 (nonprotein
coding) (MALAT1), noncoding RNA
(NR 002819)
3 0 0 3.54 1.31–9.97
MAPK3 A 23 P37910
Mitogen-activated protein kinase 3
(MAPK3), transcript variant 1, mRNA
(NM 002746)
42 1.70 1.30 2.01 0.40–2.55
NFRκB A 23 P24485
nuclear factor related to kappaB binding
protein (NFRκB) , transcript variant 2,
mRNA (NM 006165)
183 1.95 1.79 1.61 0.63–3.25
RAB17 A 23 P5778
RAB17, member RAS oncogene family
(RAB17), mRNA (NM 022449) 10 0 0 1.84 0.23–4.36
RASAL1 A 23 P139600
RAS protein activator like 1 (GAP1 like)
(RASAL1), mRNA (NM 004658) 140 2.04 1.65 1.46 0.38–2.41
RASD1
A 23 P118392 RAS, dexamethasone-induced 1
(RASD1), mRNA (NM 016084)
105 2.04 1.55 3.14 0.88–21.55
A 24 P348006 27 0 0 2.69 0.85–12.90
RHOB A 23 P51136
ras homolog gene family, member B
(RHOB), mRNA (NM 004040) 16 0 0 1.99 0.51–2.96
RHOU A 23 P114814
ras homolog gene family, member U
(RHOU), mRNA (NM 021205) 122 1.75 1.55 2.68 0.71–3.65
RHOV A 23 P117912
Rho-related GTP-binding protein RhoV
(Wnt-1 responsive Cdc42 homolog
2)(WRCH-2)(CDC42-like GTPase
2)(GTP-binding protein-like 2) (Rho
GTPase-like protein ARHV)
(ENST00000220507)
184 1.94 1.79 1.60 0.25–5.45
as DUSP1,9 as well as genes earlier identified as diﬀerentially
expressed in cancer (MAPK,MALAT1,RASD1, etc) (Table 3).
Gene functional classification in DAVID of the upreg-
ulated genes showed enrichment for four groups (kinase/
phosphatase, Ras, negative regulation of transcription, and
transmembrane) while the downregulated genes mainly
correspond to transmembrane proteins (Table 4). Gene
function was also analyzed by Ingenuity Pathways Analysis
(IPA) and includes “cellular movements,” “connective tis-
sue development and movement” and “cellular growth
and proliferation” (Figure 2). IPA also identified molecular
networks connecting several of the genes: FOSB, ERK,
MAPK3, CYR61, and the RAS-genes (Figure 3(a)); DUSP1,
ERK1/2, P38MAPK, DUSP9, and RASD1 (Figure 3(b));
CYR61 and NFRκB (Figure 3(c)) amongst other (Supple-
mentary Figure 3).
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Table 4: Gene functional classification (DAVID) of the diﬀerently expressed genes.
Gene name Agilent ID Description
Gene group 1
Enrichment score: 2.11
Kinase/phosphatase
DCAKD A 24 P58331 Dephospho-CoA kinase domain containing
SIK2 A 23 P138957 Salt-inducible kinase 2
ITPKC A 23 P208369 Inositol 1,4,5-trisphosphate 3-kinase C
DAK A 23 P36129 Dihydroxyacetone kinase 2 homolog (S. cerevisiae)
RIPK4 A 23 P211267 Receptor-interacting serine-threonine kinase 4
CHKA A 23 P136135 Choline kinase alpha
DDR1
A 23 P93311,
A 24 P367289 Discoidin domain receptor tyrosine kinase 1
STK35 A 24 P940537 Serine/threonine kinase 35
ACTR3B A 23 P123193 ARP3 actin-related protein 3 homolog B (yeast)
INO80 A 24 P39454 INO80 homolog (S. cerevisiae)
EPHA1 A 23 P157333 EPH receptor A1
BCR A 24 P15270 Breakpoint cluster region
CAMK1D A 23 P124252 Calcium/calmodulin-dependent protein kinase ID
HISPPD2A A 23 P205818 Histidine acid phosphatase domain containing 2A
Gene group 2
Enrichment score: 1.35
Ras
RHOB A 23 P51136 Ras homolog gene family, member B
RHOV A 23 P117912 Ras homolog gene family, member V
RASD1
A 24 P348006,
A 23 P118392 RAS, dexamethasone-induced 1
RAB17 A 23 P5778 RAB17, member RAS oncogene family
RHOU A 23 P114814 Ras homolog gene family, member U
Gene group 3
Enrichment score: 1.26
Negative regulation of transcription
ARID5B A 23 P97871 AT rich interactive domain 5B (MRF1-like)
COBRA1 A 23 P148150 Cofactor of BRCA1
TH1L A 24 P222126 TH1-like (Drosophila)
FOXD3 A 23 P46560 Forkhead box D3
EID2 A 23 P365844 EP300 interacting inhibitor of diﬀerentiation 2
Gene group 4
Enrichment score: 0.42
Transmembrane
PQLC1 A 24 P181677 PQ loop repeat containing 1
RNF215 A 32 P420563 Ring finger protein 215
KIAA1305 A 23 P129005 KIAA1305
TMEM49 A 32 P9753 Transmembrane protein 49
F11R A 24 P319369 F11 receptor
RBM8A A 23 P305335 Gonadotropin-releasing hormone (type 2) receptor 2
KIAA0922 A 23 P257250 KIAA0922
TSPAN12 A 23 P145984 Tetraspanin 12
DGCR2 A 24 P125881 DiGeorge syndrome critical region gene 2
PCDH1 A 23 P213359 Protocadherin 1
LMBRD2 A 32 P8952 LMBR1 domain containing 2
GPR65 A 23 P14564 G protein-coupled receptor 65
EVI2B A 23 P66694 Ecotropic viral integration site 2B
RTF1 A 24 P93741 RFT1 homolog (S. cerevisiae)
TMEM19 A 24 P358976 Transmembrane protein 19
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Table 4: Continued.
Gene name Agilent ID Description
GPR155 A 23 P335958 G protein-coupled receptor 155
OSMR A 24 P145134 Oncostatin M receptor
TMEM97 A 32 P201521 Transmembrane protein 97
PTPRE A 24 P213503,
A 24 P213494
Protein tyrosine phosphatase, receptor type, E
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Figure 1: Unsupervised (a) and supervised (c) CA plots of mRNA expression in pre- and postoperative breast cancer tumours, and
their corresponding clustering maps (b, d). The samples are marked by their respective numbers followed by either B, which defines the
preoperative samples, or T, which defines the postoperative samples. The unsupervised chart was made using all 18,189 genes (24,105
probes) expressed on the microarrayss whereas for the supervised only the 228 genes (235 probes) with FDR < 2.5% from paired SAM were
used.
3.2. Quantitative RT- PCR Validation. To confirm the results
of the microarray experiment, qRT-PCR was performed
using primer-probe pairs for the top significant genes. The
genes were selected to contain both up- and downregulated
genes. The microarray and the qRT-PCR results were in
agreement with the following genes (Figure 4 and Table 2):
ACTB, CYR61, DUSP1, EVI2b, FOSB, GAPDH, and RASD1.
3.3. Histological Analysis versus Gene Expression Analysis.
Immunohistochemistry was performed on the pre- and the
postoperative samples. Overall the tumour content in the two
samples were comparable and there was no systematic bias
(Table 1), indicating that the gene expression as measured
by microarray is comparable in the pairs. In addition, ER
and PGR status for the pre- and postoperative specimen were
similar (Table 1).
4. Discussion
Microarray studies have influenced breast cancer research
over the last decade revealing breast cancer as a heteroge-
neous disease opening for individual treatment in a clinical
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Figure 2: The most significantly enriched biological categories as identified with Ingenuity Pathway Analysis. For each category −log(P
value) is reported.
perspective. Therefore, the results from microarray studies
need to be validated. Multiple studies have generated diﬀer-
ent gene list and studied the reproducibility and correlation
with prognosis [20–22]. Despite the diﬀerence in develop-
ment of these signatures and the limited overlap in gene
identity, they show similar prognostic performance, adding
to the growing evidence that these prognostic signatures
are of clinical importance [20]. There are two prospective
ongoing studies, the MINDACT trial [23] in Europe and
TAILORx [24] in USA which will evaluate the prognostic
potential of this technology.
One important question may be if the diﬀerences in
gene expressions are related to tumour biology or reflect
the surgical trauma of the patient or the manipulation of
the tumour tissue during the operative procedure or the
time of specimen handoﬀ. If altered gene expression is
caused by such exogenous factors, the results may diﬀer
considerably between studies depending on the operative
procedure and the time spent at the operation before taking
the tissue samples. It is therefore important to evaluate if
gene expression patterns diﬀer between biopsies taken before
and after surgical procedure. This has been done in our
study with 13 patients and the gene list of 228 genes was
dominated by stress-related genes like CYR61, MALAT1,
RASD1, CX3CL1, FOSB, and CYP2D6. Some of these genes
have been studied by others in relation to oxidative stress
[25–27] and also psychological stress [28]. These genes have
diﬀerent functions all included in very important pathways
with strong hubs such as MAPK3, NFRκB, FOS, and ERK.
Upregulation of Fos has been associated with breast
cancer in a number of studies [29–31]. The fos-gene
family consists of 4 members: FOS, FOSB, FOSL1, and
FOSL2. These genes encode leucine zipper proteins that
can dimerise with proteins of the jun-family, and the
Fos-proteins have been implicated as regulators of cell
proliferation, diﬀerentiation, and transformation. Another
gene, CYR61 (cysteine-rich, angiogenic inducer, 61), most
strongly associated to diﬀerential expression in pre- and
postoperative samples, belongs to the CCN-family [32] and
mediates cell proliferation, survival, and apoptosis. Acting
as an extracellular matrix-associated signalling molecule,
CYR61 promotes the adhesion of endothelial cells through
interaction with the integrin αvβ3 and augments growth
factor-induced DNA synthesis in the same cell type [33].
In this aspect, it is both chemotactic and angiogenic, two
properties important for tumour growth and vascularisation.
CYR61 is claimed to play a critical role in oestrogen, as well
as growth factor-dependent breast tumour growth [34]. In
our list of genes, CYR61 is repeatedly connected in most of
the involved pathways. Further studies will be necessary to
confirm and explain this association.
It is of particular importance to take into considera-
tion knowledge about gene expression diﬀerences in pre-
and postoperative tissue samples in the case of treatment
response studies in the neoadjuvant setting, when the first
sample is frequently taken by biopsy and the second during
operation. In a study comparing gene expression profiles
before and after doxorubicin and cyclophosphamide neoad-
juvant chemotherapy [35] one of the genes upregulated after
the first chemotherapy treatment was DUSP1. Expression
of this gene may be associated with resistance to further
administration of chemotherapy. In our study DUSP1 was
one of the significantly upregulated genes in postoperative
tissue. DUSP1 is a stress response gene of the mitogen-
activated protein (MAP) kinase phosphatase family and is
located in the cytoplasm, mitochondria, and the nucleus.
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Figure 3: Most enriched molecular networks showing interactions between the significant genes (according to SAM)—(a) FOSB, ERK,
MAPK3, CYR61, and the RAS-genes; (b) DUSP1, ERK1/2, P38MAPK, DUSP9, and RASD1; (c) CYR61 and NFRκB. The gene identifiers and
corresponding expression values were uploaded into in the Ingenuity Pathway Analysis. Networks were then algorithmically generated based
on their connectivity in Ingenuity’s Knowledge Base. Molecules are represented as nodes, and the biological relationship between two nodes
is represented as an edge (line). The intensity of the node colour indicates the degree of (red) up- or (green) downregulation. Nodes are
displayed using various shapes that represent the functional class of the gene product.
The gene has been shown to be overexpressed in human
breast cancer [36] through diﬀerent signalling pathways. One
important pathway is in response to stress which is mediated
in part through the p38 MAPK pathway. Later studies
have implicated that DUSP1 is controlled by p53 during
cellular response to oxidative stress [37]. A similar discussion
could be relevant on molecular profiling of inflammatory
breast cancer [29], where DUSP1 was also among the
genes suggested to be useful diagnostic and prognostic
markers. Our study suggests that such findings have to (1)
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Table 5: Intrinsic subtypes of the tumours. Samples with all correlations < 0.1 were not assigned to any subtype.
Patient no. Sample type
Score
Subtype
LumA LumB ERBB2 Normal Basal Max
2
Preoperative −0.050 0.231 0.103 −0.191 −0.034 0.231 Luminal B
Postoperative −0.081 0.193 0.010 0.011 0.062 0.193 Luminal B
3
Preoperative −0.465 0.213 0.215 −0.061 0.616 0.616 Basal-like
Postoperative −0.454 0.177 0.190 0.010 0.668 0.668 Basal-like
4
Preoperative 0.064 0.152 −0.058 −0.268 −0.085 0.152 Luminal B
Postoperative 0.085 0.063 0.017 −0.271 −0.227 0.085 NA
5
Preoperative −0.001 0.032 −0.028 0.014 −0.116 0.032 NA
Postoperative −0.050 0.088 −0.061 −0.056 −0.079 0.088 NA
6
Preoperative −0.454 0.067 0.477 −0.017 0.374 0.477 ERBB2
Postoperative −0.576 0.096 0.531 −0.015 0.410 0.531 ERBB2
7
Preoperative 0.234 0.031 −0.165 −0.212 −0.224 0.234 Luminal A
Postoperative 0.123 −0.115 −0.106 0.067 −0.185 0.123 Luminal A
8
Preoperative −0.117 −0.011 0.222 −0.066 0.031 0.222 ERBB2
Postoperative −0.066 −0.060 0.144 −0.065 −0.039 0.144 ERBB2
9
Preoperative −0.127 −0.189 0.149 0.188 0.055 0.188 Normal-like
Postoperative −0.040 −0.220 0.077 0.266 0.005 0.266 Normal-like
10
Preoperative 0.032 0.039 −0.025 −0.085 −0.138 0.039 NA
Postoperative −0.003 0.218 −0.082 −0.201 −0.035 0.218 Luminal B
11
Preoperative −0.269 0.260 0.242 −0.163 0.217 0.260 Luminal B
Postoperative −0.147 0.292 0.132 −0.174 0.086 0.292 Luminal B
13
Preoperative −0.266 0.130 0.166 −0.002 0.211 0.211 Basal-like∗
Postoperative −0.105 0.246 0.089 −0.197 0.007 0.246 Luminal B∗
14
Preoperative 0.169 −0.111 −0.142 −0.017 −0.170 0.169 Luminal A∗
Postoperative 0.068 −0.175 −0.092 0.196 −0.026 0.196 Normal-like∗
15
Preoperative 0.356 −0.013 −0.328 −0.188 −0.338 0.356 Luminal A
Postoperative 0.223 −0.065 −0.131 −0.094 −0.349 0.223 Luminal A
∗Diﬀerent subtypes in the pre- and postoperative samples.
demonstrate upregulation above the one observed here by
us attributable to the pre- and postoperative factors and (2)
that deregulation attributable to the pre- and postoperative
factors is similar in the compared case/control or treatment
arm groups.
In the present study, it is not possible to separate the
eﬀects of operative manipulation, anaesthesia, or the injec-
tion of radioactive substance to examine spread of cancer
cells. For the latter, we should have had a biopsy after the
application of radioactivity not before operation. However,
both ethical and logistical considerations make collection
of such a sample infeasible. Wong et al. [11] studied the
eﬀects of timing of fine-needle aspiration biopsies. Using
hierarchical clustering analysis, they found 12 genes to be
diﬀerentially expressed before and after surgery, which were
in agreement with our study all fos-related. However, it was
unclear whether any other treatment, like sentinel node, was
given to patients between the two time points. It has been
previously shown that both fine-needle aspiration biopsy and
central core biopsy yield a similar quality and quantity of
total RNA and that microarray profiles are mainly the same
[38]. Microscopic cell counts have demonstrated that there
are more stromal cells present in core biopsies compared to
fine-needle biopsies [38], and the core biopsy is therefore
needed for the complete histological examination.
Another confounding factor in the analysis of gene
expression profiles of breast cancers is intratumour hetero-
geneity [39, 40]. Even though this study was not designed
to analyze this, molecular subclassification [41] of the
samples did in a few cases give diﬀerent result for the
pre- and postoperative samples (Table 5). Interference from
surrounding normal tissue is not likely since the overall gene
expression profiles of the pre- and postoperative samples
were very similar and distinct from that of adjacent normal
tissue (Supplementary Figure 1), thus, suggesting true cases
of intratumour heterogeneity.
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Figure 4: Relative expression of selected genes on microarrays
(upwards) and qRT-PCR (downwards). Values shown are mean
expression ±SE. For easier comparison, both the microarray and
qRT-PCR values were gene-centered.
As we have seen there are genes that are diﬀerently
expressed between the pre- and postoperative samples. We
compared our gene lists to some of the publically avai-
lable gene list to see if there were any overlapping genes.
The Oncotype DX consists of 21 genes, 16 cancer related
genes, and 5 reference genes [42]. One of these is also
found in our gene list which diﬀers between pre- and
postoperative samples, namely, GRB7, which is upregulated
in the postoperative samples. GRB7 was associated with
an increased risk of recurrence in TNBC (tripple negative
breast cancer) treated with adjuvant doxorubicin-containing
chemotherapy, suggesting that GRB7 or GRB7-dependent
pathways may serve as potential biomarkers for therapeutic
targets [43, 44]. We have shown that this gene is upregulated
in the postoperative sample. Even though the gene has been
well characterized in vitro [45–47], it is of interest that we
find it in the list of genes separating pre- and postoperative
samples.
We also wanted to compare the 70 genes listed in the
Mammaprint which were based on the intrinsic gene list [6].
As with the Oncotype DX, there was only one single gene
(NDRG1) in common for the 70 gene list in Mammaprint
with our gene list separating pre- and postoperative samples.
NDRG1 (N-myc downstream-regulated gene 1) is a member
of the N-myc downregulated gene family which belongs to
the alpha/beta hydrolase superfamily. The protein encoded
by this gene is a cytoplasmic protein involved in stress
responses, hormone responses, cell growth, and diﬀerenti-
ation. The encoded protein is necessary for p53-mediated
caspase activation and apoptosis. Expression of this gene
may be a prognostic indicator for several types of cancer
(provided by RefSeq, May 2012). The gene is significantly
upregulated in the postoperative samples of the present
study. It is known to be induced by stress, through hypoxia
[48], like many of the other genes mentioned above.
Low expression of NDRG1 is correlated with poor
clinical outcome in breast cancer [49]. It has also been
shown that expression of NDRG1 is downregulated upon
estradiol stimulation, and its expression is correlated with
favorable prognosis in breast cancer patients [50]. On the
other hand, induction of its diﬀerentiation is considered
a promising alternative or complementary to standard
anticancer chemotherapy. One may speculate why this
gene is upregulated in the postoperative samples. Stress is
probably the cause, but since the gene is a positive predictive
factor, can we then say that we place the tumor into a
diﬀerent prognostic group simply because of the stress of
the procedure. Fotovati et al. [51] concluded that NDRG1
could be used as a biomarker for diﬀerentiation of breast
cancer for both diagnostic and therapeutic purposes. Still it
is very important to be aware of at what material the gene is
measured upon.
Our study shows the expression profiles found in the
analyses of breast cancer tissue must be evaluated with
caution. Diﬀerent profiles may simply be result of diﬀerences
in the surgical trauma and timing of when samples are taken,
and not necessarily associated with tumor biology.
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